EX-99.1 2 exhibit991-8xk.htm EX-99.1

Exhibit 99.1

The following are certain preliminary results of selected unaudited financial and other information of Johnson & Johnson for the fiscal three and six months ended July 2, 2023 and actual unaudited financial results of Johnson & Johnson for the three and six months ended July 3, 2022. Johnson & Johnson has provided certain preliminary results below; however, its closing procedures for the fiscal three and six months ended July 2, 2023 are not yet complete. Johnson & Johnson’s actual results for the fiscal three and six months ended July 2, 2023 remain subject to the completion of management’s final review and Johnson & Johnson’s other closing procedures, or subsequent events, as well as the completion of the review of Johnson & Johnson’s financial statements. Accordingly, you should not place undue reliance on these preliminary results set out below, which may differ from actual results. During the course of the preparation of Johnson & Johnson’s unaudited consolidated financial statements and the notes thereto, additional items that require adjustments to the preliminary results presented below may be identified.

The preliminary financial data of Johnson & Johnson included below has been prepared by, and is the responsibility of, Johnson & Johnson’s management. Johnson & Johnson's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

The preliminary and actual results of Johnson & Johnson provided below do not represent a comprehensive statement of Johnson & Johnson’s financial results and should not be viewed as a substitute for unaudited consolidated financial results prepared in accordance with GAAP. In addition, the preliminary results for the fiscal three and six months ended July 2, 2023 are not necessarily indicative of the results to be achieved in any future period.

OVERALL FINANCIAL RESULTS:

			Q2
($ in Millions, except EPS)			2023 (Preliminary)			2022 (Actual)			% Change
Reported Sales			$25,530			$24,020			6.3%
Net Earnings/(Loss)			$5,144			$4,814			6.9%
EPS (diluted)			$1.96			$1.80			8.9%

REGIONAL SALES RESULTS:

Q2									% Change
($ in Millions)			2023 (Preliminary)			2022 (Actual)			Reported
U.S.			$13,444			$12,197			10.2%
International			12,086			11,823			2.2
Worldwide			$25,530			$24,020			6.3%

Note: values may have been rounded

SEGMENT SALES RESULTS:

Q2									% Change
($ in Millions)			2023 (Preliminary)			2022 (Actual)			Reported
Consumer Health			$4,011			$3,805			5.4%
Pharmaceutical			13,731			13,317			3.1
MedTech			7,788			6,898			12.9
Worldwide			$25,530			$24,020			6.3%

Note: Values may have been rounded

---

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)						SECOND QUARTER
																		Percent Change
						2023 (Preliminary)						2022 (Actual)						Total
Sales to customers by
geographic area
U.S.						$	13,444					12,197						10.2		%
Europe						5,894						6,085						(3.1)
Western Hemisphere excluding U.S.						1,713						1,536						11.5
Asia-Pacific, Africa						4,479						4,202						6.6
International						12,086						11,823						2.2
Worldwide						$	25,530					24,020						6.3		%

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)						SIX MONTHS
																		Percent Change
						2023 (Preliminary)						2022 (Actual)						Total
Sales to customers by
geographic area
U.S.						$	25,961					23,611						10.0		%
Europe						12,226						12,109						1.0
Western Hemisphere excluding U.S.						3,300						3,018						9.3
Asia-Pacific, Africa						8,789						8,708						0.9
International						24,315						23,835						2.0
Worldwide						$	50,276					47,446						6.0		%

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

---

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)						SECOND QUARTER																		SIX MONTHS
																		Percent Change																		Percent Change
						2023 (Preliminary)						2022 (Actual)						Total						2023 (Preliminary)						2022 (Actual)						Total
Sales to customers by
segment of business
Consumer Health
U.S.						$	1,787					1,687						6.0		%				$	3,522					3,244						8.6		%
International						2,224						2,118						5.0						4,341						4,147						4.7
						4,011						3,805						5.4						7,863						7,391						6.4
Pharmaceutical (1)
U.S.						7,818						7,159						9.2						14,841						13,791						7.6
International						5,913						6,158						(4.0)						12,303						12,395						(0.7)
						13,731						13,317						3.1						27,144						26,186						3.7
Pharmaceutical excluding COVID-19 Vaccine (1)
U.S.						7,818						7,114						9.9						14,841						13,671						8.6
International						5,628						5,659						(0.5)						11,271						11,514						(2.1)
						13,446						12,773						5.3						26,112						25,185						3.7
MedTech
U.S.						3,839						3,351						14.6						7,598						6,576						15.5
International						3,949						3,547						11.3						7,671						7,293						5.2
						7,788						6,898						12.9						15,269						13,869						10.1
U.S.						13,444						12,197						10.2						25,961						23,611						10.0
International						12,086						11,823						2.2						24,315						23,835						2.0
Worldwide						25,530						24,020						6.3						50,276						47,446						6.0
U.S.						13,444						12,152						10.6						25,961						23,491						10.5
International						11,801						11,324						4.2						23,283						22,954						1.4
Worldwide excluding COVID-19 Vaccine (1)						$	25,245					23,476						7.5		%				$	49,244					46,445						6.0		%

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1)Refer to supplemental sales reconciliation schedules.

---

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)						SECOND QUARTER
						2023 (Preliminary)												2022 (Actual)												Percent Increase (Decrease)
						Amount						Percent to Sales						Amount						Percent to Sales
Sales to customers						$	25,530					100.0						$	24,020					100.0						6.3
Cost of products sold						8,212						32.2						7,919						33.0						3.7
Gross Profit						17,318						67.8						16,101						67.0						7.6
Selling, marketing and administrative expenses						6,665						26.1						6,226						25.9						7.1
Research and development expense						3,829						15.0						3,703						15.4						3.4
Interest (income) expense, net						(23)						(0.1)						(26)						(0.1)
Other (income) expense, net*						(60)						(0.2)						273						1.1
Restructuring						145						0.5						85						0.4
Earnings before provision for taxes on income						6,762						26.5						5,840						24.3						15.8
Provision for taxes on income						1,618						6.4						1,026						4.3						57.7
Net earnings						$	5,144					20.1						$	4,814					20.0						6.9
Net earnings per share (Diluted)						$	1.96											$	1.80											8.9
Average shares outstanding (Diluted)						2,625.7												2,667.9
Effective tax rate						23.9		%										17.6		%

*    Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.

---

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)						SIX MONTHS
						2023 (Preliminary)												2022 (Actual)												Percent Increase (Decrease)
						Amount						Percent to Sales						Amount						Percent to Sales
Sales to customers						$	50,276					100.0						$	47,446					100.0						6.0
Cost of products sold						16,607						33.0						15,517						32.7						7.0
Gross Profit						33,669						67.0						31,929						67.3						5.4
Selling, marketing and administrative expenses						12,803						25.5						12,164						25.6						5.3
Research and development expense						7,392						14.7						7,165						15.1						3.2
In-process research and development						49						0.1						610						1.3
Interest (income) expense, net						(43)						(0.1)						(38)						(0.1)
Other (income) expense, net*						7,168						14.3						171						0.4
Restructuring						275						0.5						155						0.3
Earnings before provision for taxes on income						6,025						12.0						11,702						24.7						(48.5)
Provision for taxes on income						949						1.9						1,739						3.7						(45.4)
Net earnings						$	5,076					10.1						$	9,963					21.0						(49.1)
Net earnings per share (Diluted)						$	1.93											$	3.73											(48.3)
Average shares outstanding (Diluted)						2,630.7												2,669.2
Effective tax rate						15.8		%										14.9		%

*    Fiscal six months Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.

---

Johnson & Johnson

Segment Sales

(Dollars in Millions)

			SECOND QUARTER																		SIX MONTHS
															% Change																		% Change
			2023 (Preliminary)						2022 (Actual)						Reported						2023 (Preliminary)						2022 (Actual)						Reported
CONSUMER HEALTH SEGMENT (1)
OTC
US			$	712					663						7.5		%				$	1,457					1,333						9.3		%
Intl			947						818						15.7						1,844						1,609						14.6
WW			1,659						1,482						12.0						3,301						2,943						12.2
SKIN HEALTH / BEAUTY
US			650						629						3.4						1,267						1,173						8.0
Intl			498						497						0.3						991						965						2.7
WW			1,148						1,126						2.0						2,258						2,138						5.6
ORAL CARE
US			173						170						1.7						332						313						6.2
Intl			225						224						0.3						427						447						(4.7)
WW			398						394						0.9						759						760						(0.2)
BABY CARE
US			99						88						12.5						195						173						12.7
Intl			261						287						(9.1)						524						557						(6.0)
WW			360						375						(4.0)						719						730						(1.6)
WOMEN'S HEALTH
US			4						3						(2.1)						7						7						(0.1)
Intl			235						228						3.5						449						452						(0.7)
WW			238						230						3.4						455						458						(0.6)
WOUND CARE / OTHER
US			149						133						12.3						264						245						7.9
Intl			58						65						(10.3)						107						117						(8.4)
WW			207						197						4.9						371						361						2.6
TOTAL CONSUMER HEALTH
US			1,787						1,687						6.0						3,522						3,244						8.6
Intl			2,224						2,118						5.0						4,341						4,147						4.7
WW			$	4,011					3,805						5.4		%				$	7,863					7,391						6.4		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment Sales

(Dollars in Millions)

									SECOND QUARTER																		SIX MONTHS
																					% Change																		% Change
									2023 (Preliminary)						2022 (Actual)						Reported						2023 (Preliminary)						2022 (Actual)						Reported
PHARMACEUTICAL SEGMENT (1) (2)
IMMUNOLOGY
US									$	2,865					2,853						0.4		%				$	5,313					5,354						(0.8)		%
Intl									1,631						1,559						4.7						3,295						3,176						3.8
WW									4,496						4,411						1.9						8,608						8,530						0.9
			REMICADE
			US						277						391						(29.3)						553						749						(26.2)
			US Exports (3)						33						44						(24.9)						74						124						(40.3)
			Intl						152						212						(28.2)						322						437						(26.2)
			WW						462						647						(28.6)						949						1,310						(27.5)
			SIMPONI / SIMPONI ARIA
			US						285						301						(5.1)						556						588						(5.4)
			Intl						244						266						(8.2)						510						549						(7.1)
			WW						529						566						(6.6)						1,066						1,137						(6.2)
			STELARA
			US						1,817						1,731						4.9						3,268						3,110						5.1
			Intl						981						868						13.0						1,974						1,777						11.1
			WW						2,797						2,599						7.6						5,241						4,887						7.2
			TREMFYA
			US						450						382						17.8						856						773						10.7
			Intl						255						214						19.4						489						413						18.4
			WW						706						597						18.3						1,346						1,187						13.4
			OTHER IMMUNOLOGY
			US						4						3						17.8						7						9						(30.2)
			Intl						0						0						—						0						0						—
			WW						4						3						17.8						7						9						(30.2)
INFECTIOUS DISEASES
US									395						415						(4.9)						787						876						(10.2)
Intl									727						901						(19.4)						1,920						1,737						10.5
WW									1,121						1,316						(14.8)						2,707						2,613						3.6
			COVID-19 VACCINE
			US						—						45						*						—						120						*
			Intl						285						499						(43.0)						1,032						881						17.1
			WW						285						544						(47.7)						1,032						1,001						3.0
			EDURANT / rilpivirine
			US						8						9						(9.0)						17						18						(5.3)
			Intl						258						215						19.9						529						454						16.4
			WW						266						225						18.6						546						473						15.6
			PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
			US						382						355						7.6						760						724						5.0
			Intl						109						110						(0.2)						208						242						(13.9)
			WW						491						464						5.8						968						965						0.3
			OTHER INFECTIOUS DISEASES
			US						5						6						(27.2)						10						14						(30.6)
			Intl						74						77						(3.5)						151						160						(5.6)
			WW						79						83						(5.2)						161						174						(7.6)

See footnotes at end of schedule

---

Johnson & Johnson

Segment Sales

(Dollars in Millions)

																		SECOND QUARTER																		SIX MONTHS
																														% Change																		% Change
																		2023 (Preliminary)						2022 (Actual)						Reported						2023 (Preliminary)						2022 (Actual)						Reported
PHARMACEUTICAL SEGMENT (1) (2) (Continued)
NEUROSCIENCE
US																		$	1,029					896						14.9		%				$	2,007					1,739						15.4		%
Intl																		764						837						(8.8)						1,590						1,735						(8.4)
WW																		1,793						1,734						3.5						3,597						3,475						3.5
			CONCERTA / methylphenidate
			US															64						38						68.2						134						73						84.0
			Intl															143						123						16.3						279						245						13.9
			WW															208						161						28.6						414						318						30.0
			INVEGA SUSTENNA / XEPLION / INVEGA
			TRINZA / TREVICTA
			US															721						691						4.3						1,434						1,352						6.0
			Intl															310						362						(14.4)						641						749						(14.5)
			WW															1,031						1,054						(2.1)						2,075						2,102						(1.3)
			SPRAVATO
			US															144						74						93.2						255						135						88.3
			Intl															25						11						*						45						20						*
			WW															169						85						98.2						300						155						93.1
			OTHER NEUROSCIENCE
			US															100						93						9.3						184						179						3.1
			Intl															286						341						(16.4)						625						721						(13.4)
			WW															386						433						(10.9)						809						900						(10.1)
ONCOLOGY
US																		2,069						1,679						23.2						3,958						3,261						21.4
Intl																		2,329						2,362						(1.4)						4,552						4,731						(3.8)
WW																		4,398						4,042						8.8						8,510						7,992						6.5
			CARVYKTI
			US															114						24						*						184						24						*
			Intl															3						—						*						5						—						*
			WW															117						24						*						189						24						*
			DARZALEX
			US															1,322						1,021						29.5						2,513						1,974						27.3
			Intl															1,110						965						15.0						2,182						1,868						16.8
			WW															2,431						1,986						22.4						4,695						3,842						22.2
			ERLEADA
			US															241						233						3.6						490						439						11.8
			Intl															326						218						49.7						619						412						50.3
			WW															567						450						25.9						1,109						850						30.4
			IMBRUVICA
			US															262						349						(24.9)						532						719						(26.0)
			Intl															579						620						(6.7)						1,136						1,288						(11.8)
			WW															841						970						(13.2)						1,668						2,008						(16.9)
			ZYTIGA / abiraterone acetate
			US															9						19						(55.2)						25						38						(34.7)
			Intl															218						486						(55.1)						447						1,006						(55.6)
			WW															227						505						(55.1)						472						1,044						(54.8)
			OTHER ONCOLOGY
			US															122						33						*						214						67						*
			Intl															92						72						27.8						162						156						3.6
			WW															214						106						*						376						224						68.0

See footnotes at end of schedule

---

Johnson & Johnson

Segment Sales

(Dollars in Millions)

															SECOND QUARTER																		SIX MONTHS
																											% Change																		% Change
															2023 (Preliminary)						2022 (Actual)						Reported						2023 (Preliminary)						2022 (Actual)						Reported
PHARMACEUTICAL SEGMENT (1) (2) (Continued)
PULMONARY HYPERTENSION
US															$	684					560						22.0		%				$	1,284					1,132						13.4		%
Intl															289						284						2.0						561						563						(0.4)
WW															972						843						15.3						1,844						1,695						8.8
			OPSUMIT
			US												328						265						23.7						601						538						11.6
			Intl												179						173						3.4						346						343						0.9
			WW												507						438						15.7						947						881						7.5
			UPTRAVI
			US												338						272						24.2						642						541						18.7
			Intl												61						56						10.0						119						112						6.6
			WW												399						328						21.8						761						653						16.6
			OTHER PULMONARY HYPERTENSION
			US												18						23						(23.8)						41						53						(23.0)
			Intl												48						55						(10.9)						95						108						(11.7)
			WW												66						78						(14.7)						136						161						(15.5)
CARDIOVASCULAR / METABOLISM / OTHER
US															776						757						2.6						1,491						1,429						4.3
Intl															174						215						(19.0)						386						453						(14.7)
WW															950						972						(2.2)						1,877						1,882						(0.3)
			XARELTO
			US												637						609						4.7						1,215						1,117						8.8
			Intl												—						—						—						—						—						—
			WW												637						609						4.7						1,215						1,117						8.8
			OTHER
			US												138						148						(6.3)						275						312						(11.8)
			Intl												174						215						(19.0)						386						453						(14.7)
			WW												313						363						(13.8)						662						765						(13.5)
TOTAL PHARMACEUTICAL
US															7,818						7,159						9.2						14,841						13,791						7.6
Intl															5,913						6,158						(4.0)						12,303						12,395						(0.7)
WW															$	13,731					13,317						3.1		%				$	27,144					26,186						3.7		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment Sales

(Dollars in Millions)

																					SECOND QUARTER																		SIX MONTHS
																																	% Change																		% Change
																					2023 (Preliminary)						2022 (Actual)						Reported						2023 (Preliminary)						2022 (Actual)						Reported
MEDTECH SEGMENT (1) (2)
INTERVENTIONAL SOLUTIONS
US																					$	908					525						73.1		%				$	1,771					1,019						73.8		%
Intl																					712						525						35.7						1,352						1,123						20.5
WW																					1,620						1,049						54.4						3,123						2,141						45.8
			ELECTROPHYSIOLOGY
			US																		609						499						22.0						1,180						969						21.7
			Intl																		587						469						25.1						1,109						1,001						10.8
			WW																		1,196						968						23.5						2,288						1,970						16.2
			ABIOMED
			US																		272						—						*						536						—						*
			Intl																		59						—						*						119						—						*
			WW																		331						—						*						655						—						*
			OTHER INTERVENTIONAL SOLUTIONS
			US																		27						26						4.5						55						51						10.8
			Intl																		67						56						20.0						125						121						2.8
			WW																		93						81						15.1						180						171						5.1
ORTHOPAEDICS
US																					1,388						1,338						3.7						2,751						2,627						4.7
Intl																					878						820						7.0						1,759						1,719						2.3
WW																					2,265						2,157						5.0						4,510						4,345						3.8
			HIPS
			US																		250						240						4.1						491						465						5.6
			Intl																		147						148						(0.8)						296						312						(5.1)
			WW																		397						388						2.2						787						777						1.3
			KNEES
			US																		221						216						2.4						447						417						7.2
			Intl																		142						133						6.3						284						271						4.8
			WW																		363						349						3.9						731						688						6.3
			TRAUMA
			US																		483						464						4.3						974						939						3.7
			Intl																		255						232						9.9						522						505						3.2
			WW																		739						696						6.1						1,496						1,444						3.6
			SPINE, SPORTS & OTHER
			US																		433						418						3.5						839						805						4.1
			Intl																		334						306						9.0						657						630						4.2
			WW																		766						724						5.8						1,495						1,436						4.2

See footnotes at end of schedule

---

Johnson & Johnson

Segment Sales

(Dollars in Millions)

															SECOND QUARTER																		SIX MONTHS
																											% Change																		% Change
															2023 (Preliminary)						2022 (Actual)						Reported						2023 (Preliminary)						2022 (Actual)						Reported
MEDTECH SEGMENT (1) (2) (Continued)
SURGERY
US															$	1,015					992						2.2		%				$	1,990					1,913						4.0		%
Intl															1,580						1,458						8.4						3,039						2,971						2.3
WW															2,594						2,450						5.9						5,028						4,884						3.0
			ADVANCED
			US												466						454						2.7						910						871						4.5
			Intl												757						702						7.8						1,430						1,431						0.0
			WW												1,222						1,156						5.8						2,340						2,302						1.7
			GENERAL
			US												548						538						1.9						1,079						1,042						3.6
			Intl												823						756						8.9						1,608						1,540						4.5
			WW												1,372						1,294						6.0						2,688						2,582						4.1
VISION
US															529						496						6.6						1,087						1,017						6.9
Intl															778						745						4.6						1,521						1,481						2.7
WW															1,308						1,241						5.4						2,608						2,498						4.4
			CONTACT LENSES / OTHER
			US												409						374						9.1						853						774						10.1
			Intl												530						519						2.2						1,039						1,030						0.9
			WW												939						894						5.1						1,892						1,804						4.9
			SURGICAL
			US												120						122						(1.1)						234						243						(3.6)
			Intl												249						225						10.1						482						451						6.7
			WW												369						347						6.2						716						694						3.1
TOTAL MEDTECH
US															3,839						3,351						14.6						7,598						6,576						15.5
Intl															3,949						3,547						11.3						7,671						7,293						5.2
WW															$	7,788					6,898						12.9		%				$	15,269					13,869						10.1		%

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1)Unaudited

(2)Certain prior year amounts have been reclassified to conform to current year product disclosures

(3)Reported as U.S. sales